We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The 6th MS Summer College in Fukuoka (3‐4 August 2019).
- Abstract
P-2 Disease-modifying drugs for patients with multiple sclerosis - reasons for choosing the right... B Yoko Warabi b Tokyo Metropolitan Neurological Hospital, Tokyo, Japan B Background b Six disease-modifying drugs (DMDs) for multiple sclerosis (MS) are currently available in Japan. P-3 The disease course of multiple sclerosis without disease-modifying drug B Katsuichi Miyamoto, Susumu Kusunoki b Kindai University School of Medicine, Osaka, Japan It is important to start disease-modifying drug (DMD) as soon as possible after diagnosis of multiple sclerosis (MS), and it is useful to continue treatment for a long time. S2-2 Pathology of multiple sclerosis and experimental autoimmune encephalomyelitis: Abnormal morph... B Yoshio Bando b Department of Anatomy, Akita University Graduate School of Medicine, Akita, Japan Recent insights into its molecular neuropathology and immunology have provided a comprehensive overview of the pathology of multiple sclerosis (MS), including demyelination and axonal loss. S4-4 Revisiting "Myelin" in MS - future neuroscience and neuroimaging research in MS B Jin Nakahara b Department of Neurology, Keio University School of Medicine, Tokyo, Japan Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS).
- Subjects
FUKUOKA-shi (Japan); NEUROMYELITIS optica; GLIAL fibrillary acidic protein; MEDICAL sciences; TRANSVERSE myelitis; CENTRAL nervous system diseases; ACUTE phase proteins
- Publication
Clinical & Experimental Neuroimmunology, 2020, Vol 11, p57
- ISSN
1759-1961
- Publication type
Article
- DOI
10.1111/cen3.12572